Pharmaron Beijing Co., Ltd, a leading Contract Research Organization (CRO) based in Beijing (HKG: 3759; SHE: 300759), has announced a comprehensive strategic partnership with the UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN). This collaboration will encompass the entire spectrum of drug development, including small molecules, macromolecules, and gene therapies, from discovery to pre-clinical and clinical development stages.
In addition to this partnership, Pharmaron plans to invest an additional RMB 91 million into Wuxi AstraZeneca CICC Venture Capital. This investment aims to combine the companies’ industry-leading resources and global experience to foster innovation in medical enterprises and bolster the overall healthcare sector.- Flcube.com
